Zavegepant - Pfizer
Alternative Names: BHV 3500; BMS-742413; BMS-742413-03; PF 07930207; Vazegepant; Vazegepant - Pfizer; Zavegepant hydrochloride; ZAVZPRETLatest Information Update: 13 Jun 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Pfizer
- Class Anti-infectives; Antiallergics; Antimigraines; Indazoles; Piperazines; Piperidines; Quinolines; Small molecules
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II/III COVID-19 respiratory infection
- Phase I Allergic asthma
Most Recent Events
- 11 Jun 2024 Pfizer plans a phase I pharmacokinetics trial in healthy adult lactating women's in USA (Intranasal) (NCT06453356)
- 10 Jun 2024 Pfizer initiates a phase I pharmacokinetics trial in healthy adult lactating women's in USA (Intranasal) (NCT06453356)
- 13 Apr 2024 Adverse events data from a phase II/III trial in Migraine presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)